In particular, as a common mutation in the association of hereditary myeloid neoplasms, understanding DDX41 mutations can help establish the strategy for surveillance and management of germline mutation carriers, and screening and early identification for stem-cell transplant donors for the patients with MDS/AML with germline DDX41 mutations. This evidence concerns the gene DDX41 and myelodysplastic syndrome.